3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase EARLY_PHASE1
2
Phase 2
2
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
16
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasm Metastasis
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Solid Tumors Refractory to Standard Therapy
1
Solid Tumors
1
Solid Tumor, Adult
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Kidney Neoplasms
1
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1
Hereditary Sensory and Autonomic Neuropathies
1
HER2-positive Breast Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Interventions
Gemcitabine
97
130-nm albumin-bound paclitaxel
47
Albumin-Bound Paclitaxel
36
Oxaliplatin
27
Fluorouracil
26
Capecitabine
20
Taxes
19
Leucovorin
19
pembrolizumab
18
Cyclophosphamide
18
Irinotecan
16
Bevacizumab
12
fludarabine
11
Nivolumab
11
Cetuximab
11
Cisplatin
10
durvalumab
8
Radiotherapy
8
spartalizumab
7
aldesleukin
7
Erlotinib Hydrochloride
7
Drug Therapy
7
avelumab
6
Radiosurgery
6
Paclitaxel
6
irinotecan sucrosofate
5
folfirinox
5
Ipilimumab
5
Injections
5
ALT-803
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Pancreatic Neoplasms
×
palbociclib
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled